{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T20:29:44Z","timestamp":1765916984864,"version":"3.48.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics: Clinical Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpedcp.2025.200187","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:23:40Z","timestamp":1760145820000},"page":"200187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report"],"prefix":"10.1016","volume":"18","author":[{"given":"Audrey","family":"Piednoir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Troussier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lagarce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpedcp.2025.200187_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1525-1470.2008.00620.x","article-title":"Cutaneous manifestations of cystic fibrosis","volume":"25","author":"Bernstein","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jpedcp.2025.200187_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpedcp.2025.200187_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del\u2013gating and \u2013residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpedcp.2025.200187_bib4","first-page":"554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jpedcp.2025.200187_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpedcp.2025.200187_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2340\/00015555-0681","article-title":"Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations","volume":"89","author":"Kosmidou","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jpedcp.2025.200187_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamadermatol.2022.5208","article-title":"Acneiform eruption following elexacaftor-tezacaftor-ivacaftor treatment in patients with cystic fibrosis","volume":"159","author":"Okroglic","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jpedcp.2025.200187_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpedcp.2025.200187_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"}],"container-title":["The Journal of Pediatrics: Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950541025000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950541025000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T20:27:01Z","timestamp":1765916821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950541025000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":9,"alternative-id":["S2950541025000493"],"URL":"https:\/\/doi.org\/10.1016\/j.jpedcp.2025.200187","relation":{},"ISSN":["2950-5410"],"issn-type":[{"type":"print","value":"2950-5410"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics: Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpedcp.2025.200187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"200187"}}